• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Esteve Pharmaceuticals to market Inbrija levodopa DPI in Spain

Esteve Pharmaceuticals has acquired the exclusive rights to market Inbrija dry powder levodopa in Spain and expects to launch the product there by the end of 2022, according to Acorda Therapeutics. Esteve will pay Acorda "a significant double-digit percent of the selling price" for Acorda to supply the product. The Inbrija DPI was approved in Europe for the … [Read more...] about Esteve Pharmaceuticals to market Inbrija levodopa DPI in Spain

Celltrion, Inhalon partner on inhaled regdanvimab for COVID-19

Inhalon Biopharma has announced that it is partnered with Celltrion to develop a nebulized formulation of regdanvimab, a monoclonal antibody for the treatment of COVID-19, which will be known as IN-006. In May 2021, Inhalon announced that it had been awarded a US Army contract worth $7 million for development of IN-006. The company says that a Phase 1 study of IN-006 … [Read more...] about Celltrion, Inhalon partner on inhaled regdanvimab for COVID-19

Leyden Labs partners with Nanopharm on antiviral nasal spray development

OINDP research and development specialist Nanopharm has partnered with Leyden Labs for development of Leyden Labs antiviral nasal spray candidates, the companies have announced. Nanopharm, which was acquired by Aptar Pharma in 2019, will develop a liquid nasal formulation in preparation for Phase 1 trials and may evaluate a powder formulation as well. In March 2021, … [Read more...] about Leyden Labs partners with Nanopharm on antiviral nasal spray development

Philip Morris announces £1 billion offer for Vectura

Philip Morris International (PMI) has announced an offer of ~£1.05 billion for the acquisition of inhalation CDMO Vectura. In May 2021, Vectura announced that it would be acquired by the Carlyle Group for £958 million. The Vectura Board has withdrawn its support for the Carlyle deal and agreed to the PMI acquisition, citing PMI's experience with aerosol delivery among … [Read more...] about Philip Morris announces £1 billion offer for Vectura

Rokote Labs gets €9 million for development of intranasal COVID vaccine

Rokote Laboratories, a spin out from the University of Helsinki and the University of Eastern Finland, has raised €9 million for development of an intranasal vaccine against the SARS-CoV-2 virus, the universities have announced. The funding, which includes €3.5 million from the Finnish Cultural Foundation, Ferring Ventures SA, and the Jenny and Antti Wihuri … [Read more...] about Rokote Labs gets €9 million for development of intranasal COVID vaccine

PureIMS, Sever Pharma Solutions, and Radboudumc partner on development of tigecycline DPI

Dutch DPI developer Pure IMS has announced a new partnership with CDMO Sever Pharma Solutions (formerly Disphar International) and Radboud University Medical Center (Radboudumc) for development of a tigecycline dry powder inhaler for the treatment of multi-drug resistant Mycobacterium abscessus lung infections. Radboudumc research has demonstrated that inhaled … [Read more...] about PureIMS, Sever Pharma Solutions, and Radboudumc partner on development of tigecycline DPI

M8 Pharmaceuticals gets Brazilian and Mexican rights to Marinomed’s Carragelose nasal spray

M8 Pharmaceuticals said that it has acquired exclusive rights to market Marinomed's Carragelose nasal spray in Brazil and Mexico. The company will market the product in those countries as Barlo nasal spray for the prevention of respiratory viruses. Carragelose nasal sprays are currently marketed over 40 countries, including Italy, Austria, Canada, China, and … [Read more...] about M8 Pharmaceuticals gets Brazilian and Mexican rights to Marinomed’s Carragelose nasal spray

FluGen gets funding from US Department of Defense for intranasal flu vaccine

FluGen said that it has received an $11.4 million grant from the United States Department of Defense for a Phase 1b study to evaluate the ability of its M2SR intranasal flu vaccine to protect against a variety of flu strains, including those like H3N2 that are mismatched to current vaccines. In February 2019, FluGen announced that a Phase 2 trial of the M2SR vaccine … [Read more...] about FluGen gets funding from US Department of Defense for intranasal flu vaccine

Altimmune halts development of AdCOVID intranasal vaccine, terminates trial of T-COVID intranasal therapeutic

Altimmune has discontinued development of its AdCOVID intranasal vaccine for the prevention of COVID-19 after the failure of a Phase 1 trial and has stopped enrollment in a Phase 1/2 trial of its T-COVID intranasal therapy for COVID-19 the company said. The FDA had cleared the IND for the Phase 1 trial of AdCOVID in February 2021; the Phase 1/2 trial of T-COVID was … [Read more...] about Altimmune halts development of AdCOVID intranasal vaccine, terminates trial of T-COVID intranasal therapeutic

Pieris announces development of inhaled anticalin for IPF, long COVID

Pieris Pharmaceuticals has announced that it will develop an inhaled anticalin known as PRS-220 for the treatment of idiopathic pulmonary fibrosis and for pulmonary fibrosis following COVID infection, with both programs slated to start in 2022. A €14.2 million grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy will fund development … [Read more...] about Pieris announces development of inhaled anticalin for IPF, long COVID

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 33
  • Page 34
  • Page 35
  • Page 36
  • Page 37
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews